AlphaMadera's AlphaVal page computes AbbVie Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ABBV as undervalued, fairly valued, or overvalued.

What is AbbVie Inc.'s fair value?

Fair value for ABBV is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ABBV?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ABBV's most recent reported fundamentals.

ABBV - AbbVie Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $279.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 37.3% above fair value

Current Price $250.88

Bear Case $156.58 37.6% downside ($156.58 - $250.88) / $250.88 = -37.6% $10.08 × 12x P/E

Fair Value $182.67 27.2% downside ($182.67 - $250.88) / $250.88 = -27.2% $10.08 × 14x P/E

Bull Case $208.77 16.8% downside ($208.77 - $250.88) / $250.88 = -16.8% $10.08 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

10.08$

Key Value Driver

Normalized P/E multiple (14x base case)

Implied Market Multiple 24.9x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $279.50 from 41 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $182.67 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 325%. Check what costs are being left out of the adjusted number.

⚠ The company pays out 288% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.

ℹ Dividend-based valuation: $193.24 (above our primary estimate by 37%). Large gaps may signal the dividend doesn't reflect full earning power.

ℹ Wall Street's average price target is $279.50 (from 41 analysts). Our estimate is 49% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples